Effect of infosheet for topical tacrolimus 0.1% and its efficacy and compliance in the treatment of atopic dermatitis
Allergy, Asthma & Respiratory Disease
; : 221-226, 2013.
Article
em Ko
| WPRIM
| ID: wpr-66334
Biblioteca responsável:
WPRO
ABSTRACT
PURPOSE:
Topical calcineurin inhibitor is recently developed topical immunomodulator, and preliminary studies showed its effectiveness in the treatment of atopic dermatitis (AD). However, some side effects including transient irritation can influence the patient compliance. So, there are some needs to improve the patient compliance. The purpose of this study was to evaluate the efficacy, safety and patient compliance with using topical tacrolimus 0.1% to treat AD when the correct information about topical tacrolimus are properly given to patients.METHODS:
We examined the medical recordings, clinical severity scoring of total 194 AD patients at 9 general hospitals in Seoul, Korea from September 2010 to August 2011. We offered an infosheet of topical tacrolimus 0.1% and the patients applied it twice a day for 2 weeks. And we measured the efficacy of the topical tacrolimus 0.1% with SCORing atopic dermatitis (SCORAD) index, patient's global assessment (PGA), and investigator's global assessment (IGA).RESULTS:
Topical tacrolimus 0.1% effectively controlled AD with a reduction of the SCORAD index from baseline 31.9 to 20.2 at 2 weeks of application. In IGA results showed 98% got improvement and in PGA, results showed 96% got improvement after treatment. Although 42.3% of the patients complained of adverse effects, these were all transient. The effect of information on topical tacrolimus 0.1% showed 34% patients could predict the side effect, 35% patients could feel safety to use, and 18% patients experienced side effect but could maintain topical calcineurin inhibitor.CONCLUSION:
Topical tacrolimus 0.1% may be an effective treatment modality for AD when patients show good compliance for applying the ointment. And properly given, the correct information may increase the patient compliance.Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Prostaglandinas A
/
Imunoglobulina A
/
Prontuários Médicos
/
Cooperação do Paciente
/
Tacrolimo
/
Complacência (Medida de Distensibilidade)
/
Calcineurina
/
Dermatite Atópica
/
Hospitais Gerais
/
Coreia (Geográfico)
Tipo de estudo:
Prognostic_studies
Limite:
Humans
País/Região como assunto:
Asia
Idioma:
Ko
Revista:
Allergy, Asthma & Respiratory Disease
Ano de publicação:
2013
Tipo de documento:
Article
País de publicação:
COREA DEL SUR
/
COREIA DO SUL
/
KR
/
SOUTH KOREA